Brief: Orchard Therapeutics Reports New Interim Data From Study For MPS-I
15/05/2020 11:20
May 15 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS PRESENTS NEW INTERIM DATA FROM
OTL-203
PROOF-OF-CONCEPT STUDY FOR MPS-I
* ORCHARD THERAPEUTICS PLC - FIRST PRIMARY OUTCOME MEASURE
MET
WITH ALL EIGHT PATIENTS ACHIEVING HEMATOLOGIC ENGRAFTMENT
* ORCHARD THERAPEUTICS PLC - ONE-YEAR FOLLOW-UP RESULTS AND
INITIATION OF REGISTRATIONAL TRIAL EXPECTED IN 2021
* ORCHARD THERAPEUTICS PLC - IMPROVED MOTOR SKILLS, STABLE
COGNITIVE SCORES AND NORMAL GROWTH SEEN IN FIRST TWO PATIENTS
* ORCHARD THERAPEUTICS PLC - ALSO EXPECTS TO RELEASE FULL
PROOF-OF-CONCEPT RESULTS AND INITIATE REGISTRATIONAL STUDY FOR
OTL-203 IN 2021
* ORCHARD THERAPEUTICS PLC - PROOF-OF-CONCEPT STUDY IS
ONGOING AND
ADDITIONAL INTERIM RESULTS ARE PLANNED TO BE REPORTED IN SECOND
HALF OF 2020
Source text for Eikon: ID:nGNX1PZmVR
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln